Volume : 10, Issue : 07, July – 2023
Title:
22.DEVELOPMENT AND VALIDATION OF NOVEL STABILITY-INDICATING RP-HPLC METHOD FOR DETERMINATION OF PITOLISANT IN BULK AND PHARMACEUTICAL DOSAGE FORM
Authors :
Padmanabh B. Deshpande*, Pratiksha Shinde, Aarti Khadtare, Rutuja Parit
A new simple, accurate and precise stability-indicating RP-HPLC analytical method has been developed and validated for the quantitative analysis of Pitolisant as bulk drug and in tablet dosage form. The objective of this study was to explore Pitolisant degradation behavior under ICH recommended stress conditions, employing a newly designed stability indicating RP-HPLC method and validating it. The method was developed on Agilent eclipse C8 (150 mm × 4.6 mm) column with Methanol: 0.05 M Phosphate Buffer (pH 5) (65: 35, v/v) as mobile phase using simple gradient elution technique. Detection was carried out at 222 nm using a photodiode array detector at ambient temperature. The retention time was found to be 3.6 min. The developed procedure was successfully validated as per ICH Q2 (R1) guidelines. The developed method was found to be linear within the range of 5-30 µg mL-1 (R2 =0.993), precise as % R.S.D. for inter-day and intra-day precision were found to be < 2 %, accurate as % recovery values in accuracy study was found to be in range of 98-102 % and sensitive as limit of detection and limit of quantitation were found to be 0.28 µg mL-1 and 0.85 µg mL-1, respectively.
Keywords: Pitolisant, Stress degradation, Stability indicating, RP-HPLC
Cite This Article:
Please cite this article in press Padmanabh B. Deshpande et al, Development And Validation Of Novel Stability-Indicating RP-HPLC Method For Determination Of Pitolisant In Bulk And Pharmaceutical Dosage Form., Indo Am. J. P. Sci, 2023; 10 (07).
Number of Downloads : 10
References:
1. Kollb-Sielecka M, Pierre D, Joseph E, Greg M, Tomas S, Haas M. The European medicines agency review of Pitolisant for treatment of narcolepsy: summary of the scientific assessment by the committee for medicinal products for human use. Sleep Med, 2017; 33: 125-129.
2. Magdalena K, Kamil K, Katarzyna S, Jacek S. The histamine H3 receptor inverse agonist pitolisant reduces body weight in obese mice. Naunyn Schmiedebergs Arch Pharmacol, 2018; 391(10): 875-881.
3. Gummadi S, Rajya Lakshmi N. Quantification of Pitolisant: A RP-HPLC study. YMER, 2022; 21(6): 896-907.
4. Ramakrishna N, Devender Reddy A, Vishwottam K, Hanumanth Rao P, Mahesh Reddy J, Gopinadh B, Nageswar Rao M. LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. Biomed chromatogr, 2013; 24(11):1431-1437.
5. Venkateswara Rao P, Leela Rani J, Roja Kumari M, Kalyani G, Sirisha G, Naveen Reddy P. Stability indicating RP-HPLC method for determination of pitolisant in bulk and pharmaceutical dosage form. International Journal of Research in Pharmacy and Chemistry, 2020; 10(1): 137-143.
6. ICH Guideline Q2A (R1), Validation of analytical procedure, text and methodology Q2 (R1) (2005)
7. ICH Guideline Q1A (R2), Stability testing of new drug substances and products Q1A (R2) (2003)
</div8